NASDAQ: BGNE
Beigene Ltd Stock

$205.62+3.96 (+1.96%)
Updated Dec 6, 2024
BGNE Price
$205.62
Fair Value Price
N/A
Market Cap
$21.94B
52 Week Low
$126.97
52 Week High
$248.16
P/E
-321.28x
P/B
6.39x
P/S
7.17x
PEG
N/A
Dividend Yield
N/A
Revenue
$3.32B
Earnings
-$860.46M
Gross Margin
83.7%
Operating Margin
-25.77%
Profit Margin
-25.9%
Debt to Equity
0.7
Operating Cash Flow
-$437M
Beta
0.85
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

BGNE Overview

BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine BGNE's potential to beat the market

Zen Rating Component Grades

N/A
Value
N/A
Growth
N/A
Momentum
N/A
Sentiment
N/A
Safety
N/A
Financials
N/A
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
BGNE
Ranked
Unranked of 554

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
$25.45A
$6.72A
$19.82A
View Top Biotech Stocks

Be the first to know about important BGNE news, forecast changes, insider trades & much more!

BGNE News

Overview

Due Diligence Score

Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BGNE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

BGNE is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BGNE is poor value based on its book value relative to its share price (6.39x), compared to the US Biotechnology industry average (5.68x)
P/B vs Industry Valuation
BGNE is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more BGNE due diligence checks available for Premium users.

Valuation

BGNE price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-321.28x
Industry
-105.55x
Market
29.86x

BGNE price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
6.39x
Industry
5.68x
BGNE is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

BGNE's financial health

Profit margin

Revenue
$1.0B
Net Income
-$121.4M
Profit Margin
-12.1%
BGNE's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
BGNE's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$5.8B
Liabilities
$2.4B
Debt to equity
0.7
BGNE's short-term assets ($3.91B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BGNE's short-term assets ($3.91B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BGNE's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
BGNE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$188.4M
Investing
-$133.9M
Financing
$12.7M
BGNE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

BGNE vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
BGNE$21.94B+1.96%-321.28x6.39x
MRNAC$17.10B+3.49%-7.65x1.43x
UTHRB$16.50B-1.26%15.21x2.71x
RPRXB$15.27B-1.82%10.08x1.49x
BNTX$29.18B+2.42%-58.35x1.42x

Beigene Stock FAQ

What is Beigene's quote symbol?

(NASDAQ: BGNE) Beigene trades on the NASDAQ under the ticker symbol BGNE. Beigene stock quotes can also be displayed as NASDAQ: BGNE.

If you're new to stock investing, here's how to buy Beigene stock.

What is the 52 week high and low for Beigene (NASDAQ: BGNE)?

(NASDAQ: BGNE) Beigene's 52-week high was $248.16, and its 52-week low was $126.97. It is currently -17.14% from its 52-week high and 61.95% from its 52-week low.

How much is Beigene stock worth today?

(NASDAQ: BGNE) Beigene currently has 1,386,034,320 outstanding shares. With Beigene stock trading at $205.62 per share, the total value of Beigene stock (market capitalization) is $21.94B.

Beigene stock was originally listed at a price of $28.32 in Feb 3, 2016. If you had invested in Beigene stock at $28.32, your return over the last 8 years would have been 626.06%, for an annualized return of 28.12% (not including any dividends or dividend reinvestments).

How much is Beigene's stock price per share?

(NASDAQ: BGNE) Beigene stock price per share is $205.62 today (as of Dec 6, 2024).

What is Beigene's Market Cap?

(NASDAQ: BGNE) Beigene's market cap is $21.94B, as of Dec 8, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Beigene's market cap is calculated by multiplying BGNE's current stock price of $205.62 by BGNE's total outstanding shares of 1,386,034,320.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.